Rani Therapeutics Holdings, Inc. (RANI)
| Market Cap | 86.64M |
| Revenue (ttm) | 1.63M |
| Net Income (ttm) | -29.67M |
| Shares Out | 99.81M |
| EPS (ttm) | -0.45 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 349,991 |
| Open | 0.890 |
| Previous Close | 0.890 |
| Day's Range | 0.850 - 0.907 |
| 52-Week Range | 0.387 - 3.870 |
| Beta | 0.66 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+764.06%) |
| Earnings Date | May 7, 2026 |
About RANI
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I c... [Read more]
Financial Performance
In 2025, RANI's revenue was $1.63 million, an increase of 58.85% compared to the previous year's $1.03 million. Losses were -$29.67 million, -1.15% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 764.06% from the latest price.
News
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025
Significant progress was made in 2025, including a major Chugai partnership, strong pipeline advances, and improved financials with a cash runway into Q4 2027. RT-114 entered phase I trials, and the company is now debt-free.
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapita...
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
SAN JOSE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneou...
Rani Therapeutics to Participate in the Evercore Healthcare Conference
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr.
CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why
Biotech stocks are lighting up the tape today, with several clinical-stage companies posting double-digit gains on fresh catalysts. From earnings beats to promising trial data and billion-dollar partn...
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
Rani Therapeutics said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical , with an option to extend it to up to five drugs, potentially bringing the total deal va...
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing
SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agonist del...
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...
Rani Therapeutics Announces Research Agreement with Chugai
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani ...
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
- Announced preclinical data demonstrating the bioequivalence of RT-114, a bispecific GLP-1/GLP-2 receptor agonist (PG-102), delivered orally via the RaniPill® capsule, to subcutaneous administration ...
Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024
Rani advanced its RaniPill platform with strong preclinical data for RT-114 and RT-116, focusing on oral obesity therapies. Financials showed reduced expenses and improved net loss, with cash sufficient into Q3 2025. RT-114 is prioritized for clinical trials in mid-2025.
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
- Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® capsule, to subcutaneous administration of PG-102 -
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
- RT-114 yielded a relative bioavailability of 111% compared to PG-102 delivered subcutaneously with comparable PK profiles, meeting the primary endpoint of demonstrating bioequivalenc e –
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
SAN JOSE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...